Jazz Pharma 8-K Hints at Executive Changes, Compensation Updates
Ticker: JAZZ · Form: 8-K · Filed: Feb 21, 2024 · CIK: 1232524
| Field | Detail |
|---|---|
| Company | Jazz Pharmaceuticals PLC (JAZZ) |
| Form Type | 8-K |
| Filed Date | Feb 21, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $700,000, $150,000, $4,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, compensation, regulation-fd
TL;DR
**Jazz Pharma just filed an 8-K about executive changes and compensation, so keep an eye out for leadership shifts!**
AI Summary
Jazz Pharmaceuticals plc filed an 8-K on February 21, 2024, reporting on Item 5.02, "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers." The filing also included information under Item 7.01, "Regulation FD Disclosure," and Item 9.01, "Financial Statements and Exhibits." This indicates potential changes in executive leadership or their compensation, as well as the disclosure of material non-public information.
Why It Matters
Changes in executive leadership or their compensation can signal strategic shifts, financial performance, or governance adjustments within Jazz Pharmaceuticals, potentially impacting investor confidence and future company direction.
Risk Assessment
Risk Level: medium — The filing indicates potential changes in leadership or compensation, which can introduce uncertainty or signal strategic shifts, warranting investor attention.
Key Players & Entities
- Jazz Pharmaceuticals plc (company) — Registrant
- February 21, 2024 (date) — Date of earliest event reported and filing date
- 001-33500 (other) — Commission File No.
- Ireland (other) — State or Other Jurisdiction of Incorporation
- 98-1032470 (other) — IRS Employer Identification No.
FAQ
What is the primary purpose of this 8-K filing by Jazz Pharmaceuticals plc?
The primary purpose of this 8-K filing is to report on Item 5.02, "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers," as well as Item 7.01, "Regulation FD Disclosure," and Item 9.01, "Financial Statements and Exhibits."
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 21, 2024.
What is the Commission File Number for Jazz Pharmaceuticals plc?
The Commission File Number for Jazz Pharmaceuticals plc is 001-33500.
In which jurisdiction is Jazz Pharmaceuticals plc incorporated?
Jazz Pharmaceuticals plc is incorporated in Ireland.
What specific items are covered in this 8-K filing?
This 8-K filing covers Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits).
Filing Stats: 983 words · 4 min read · ~3 pages · Grade level 11.9 · Accepted 2024-02-21 07:46:01
Key Financial Figures
- $0.0001 — istered Ordinary shares, nominal value $0.0001 per share JAZZ The Nasdaq Stock Mar
- $700,000 — 's annual base salary will initially be $700,000, and he will be a participant in the Co
- $150,000 — on will also be paid a signing bonus of $150,000. In connection with his appointment a
- $4,000,000 — with an approximate grant date value of $4,000,000, consisting of an equal mix of restrict
Filing Documents
- d579255d8k.htm (8-K) — 27KB
- d579255dex991.htm (EX-99.1) — 8KB
- 0001193125-24-040726.txt ( ) — 162KB
- jazz-20240221.xsd (EX-101.SCH) — 3KB
- jazz-20240221_lab.xml (EX-101.LAB) — 18KB
- jazz-20240221_pre.xml (EX-101.PRE) — 11KB
- d579255d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits 99.1 Press Release of Jazz Pharmaceuticals plc, dated February 21, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY By: /s/ Neena Patil Name: Neena Patil Title: Executive Vice President and Chief Legal Officer Date: February 21, 2024